Haleon (HLN) Financial Analysis & Valuation | Quarter Chart
Haleon (HLN)
HLNPrice: $9.33
Fair Value: 🔒
🔒score
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, a... more
Haleon plc engages in the research and development, manufacture, and sale of various consumer health... more
Description
Shares
| Market Cap | $41.19B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | GB | CEO | Brian James McNamara |
| IPO Date | 2022-07-25 | CAGR | 0.04% |
| Employees | 24,561 | Website | www.haleon.com |
| Div. Yield | 2.05% | Payout Ratio | 0.4% |
| Buy Back Yield | 1.59% | Total Yield | 3.64% |
HLN chart loading...
Fundamentals
Technicals
| Enterprise Value | $40.59B | P/E Ratio | 23.34 |
| Forward P/E | 15.44 | PEG Ratio | 0.21 |
| P/S Ratio | 3.73 | P/B Ratio | 1.92 |
| P/CF Ratio | 30.52 | P/FCF Ratio | 32.92 |
| EPS | $0.4 | EPS Growth 1Y | 40.55% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 13.67% | Gross Margin | 0.61% |
| Operating Margin | 0.19% | Profit Margin | 0.13% |
| ROE | 0.06% | ROA | 0.03% |
| ROCE | 0.06% | Current Ratio | 0.92 |
| Quick Ratio | 0.71 | Cash Ratio | 0.27 |
| Debt/Equity | 0.52 | Interest Coverage | 12.83 |
| Altman Z Score | 3.34 | Piotroski Score | 8 |